



Nasal Steroids
Effective April 17, 2019

Plan	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input checked="" type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Prescriptions that meet the initial step therapy requirements will adjudicate automatically at the point of sale. If the prescription does not meet the initial step therapy requirements, the prescription will deny with a message indicating that prior authorization (PA) is required. Refer to the criteria below and submit a PA request for the members who do not meet the initial step therapy requirements at the point of sale.

Initial Step-Therapy Requirements:

First-Line: Medications listed on first-line are covered without prior-authorization.

Second-Line: Second-line medications will pay if the member has filled all first-line medications or a second-line medication within the past 180 days.

Coverage Guidelines

FIRST-LINE	SECOND-LINE
flunisolide (<i>compare to Nasalide 25mcg</i>) flunisolide (<i>compare to Nasarel 29mcg</i>) fluticasone propionate (<i>compare to Flonase</i>)	budesonide nasal Triamcinolone (<i>compare to Nasacort AQ</i>)

If a member does not meet the initial step therapy requirements, then approval of a second-line medication will be granted if the member meets the following criteria:

Triamcinolone Nasal:

1. The member has had a documented side effect, allergy or treatment failure with fluticasone propionate (Flonase®) **AND**
2. The member has had a documented side effect, allergy or treatment failure with flunisolide **AND**



3. The member has had a documented side effect, allergy or treatment failure with Nasacort Allergy 24Hr OTC (triamcinolone)

Budesonide Nasal:

1. The member is pregnant **OR**
1. The member has had a documented side effect, allergy or treatment failure with fluticasone propionate (Flonase®) **AND**
2. The member has had a documented side effect, allergy or treatment failure with flunisolide **AND**
3. The member has had a documented side effect, allergy or treatment failure with Rhinocort Allergy OTC (budesonide) **AND**
4. The member has had a documented side effect, allergy or treatment failure with Nasacort Allergy 24Hr OTC (triamcinolone)

Limitations

1. Approvals will be granted for 12 months.

References

1. Mylan-Budesonide AQ (budesonide) [product monograph]. Etobicoke, Ontario, Canada: Mylan Pharmaceuticals ULC; May 2018
2. Flunisolide [package insert]. Tampa (FL): Bausch & Lomb Inc.; 2012 Dec.
3. Flunisolide [package insert]. Weston (FL): Apotex Corp.; 2012 Jul.
4. Flonase (fluticasone) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; January 2019
5. Nasacort AQ (triamcinolone acetate spray) [prescribing information]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; October 2018
6. Namazy J, Schatz M. The treatment of allergic respiratory disease during pregnancy. *J Investig Allergol Clin Immunol*. 2016;26(1):1-7

Review History

06/18/07 – Reviewed
10/22/07 – Bi-weekly Drug File
11/26/07 – Reviewed
06/16/08 – Reviewed
09/22/08 – Reviewed
06/15/09 – Updated
06/21/10 – Reviewed
08/18/10 – Adjudication rules update
06/27/11 – Reviewed
08/01/11 – Triamcinolone
06/25/12 – Reviewed
12/01/12 – RxAuth
04/15/13 – Qnasl & Zetonna
06/24/13 – Reviewed
04/28/14 – Nasacort OTC
04/27/15 – Reviewed
04/25/16 – Rhinocort Allergy
07/2016 – Added Flonase Sensimist; removed Veramyst
04/17/19 - Updated



Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.